Stockreport

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Skye Bioscience, Inc.  (SKYE) 
PDF Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected enrollment enables full top-line Phase 2a data [Read more]